329 related articles for article (PubMed ID: 36755576)
1. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
Yao Y; Chen H; Lou M; Chen T
Front Genet; 2023; 14():1071694. PubMed ID: 36755576
[No Abstract] [Full Text] [Related]
2. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
Front Immunol; 2022; 13():954440. PubMed ID: 36059510
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes based on cuproptosis regulators and immune infiltration in kidney renal clear cell carcinoma.
Liu A; Li Y; Shen L; Li N; Zhao Y; Shen L; Li Z
Front Genet; 2022; 13():983445. PubMed ID: 36338990
[TBL] [Abstract][Full Text] [Related]
6. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
[TBL] [Abstract][Full Text] [Related]
7. Identification of the Prognosis Value and Potential Mechanism of Immune Checkpoints in Renal Clear Cell Carcinoma Microenvironment.
Liao G; Wang P; Wang Y
Front Oncol; 2021; 11():720125. PubMed ID: 34336706
[TBL] [Abstract][Full Text] [Related]
8. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
Bian Z; Fan R; Xie L
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
[TBL] [Abstract][Full Text] [Related]
9. Integrated analyses reveal the prognostic, immunological features and mechanisms of cuproptosis critical mediator gene FDX1 in KIRC.
Wang Y; Zhang X; Chen G; Xing Q; Zhu B; Wang X
Genes Immun; 2023 Aug; 24(4):171-182. PubMed ID: 37430022
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
11. Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator
Zeng S; Zhang H; Zhang D; Hu X; Song L
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292610
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis gene-related, neural network-based prognosis prediction and drug-target prediction for KIRC.
Liu Y; Shao Y; Hao Z; Lei X; Liang P; Chang Q; Wang X
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38131663
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
Front Genet; 2022; 13():923737. PubMed ID: 35991547
[No Abstract] [Full Text] [Related]
14. Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment.
Xie M; Cheng B; Yu S; He Y; Cao Y; Zhou T; Han K; Dai R; Wang R
Cells; 2022 Dec; 12(1):. PubMed ID: 36611966
[TBL] [Abstract][Full Text] [Related]
15. ARPC1B is a novel prognostic biomarker for kidney renal clear cell carcinoma and correlates with immune infiltration.
Tang YF; Qiao B; Huang YB; Wang M
Front Mol Biosci; 2023; 10():1202524. PubMed ID: 37795220
[No Abstract] [Full Text] [Related]
16. Confirmation of the predictive function of cuproptosis-related gene FDX1 in clear cell renal carcinoma using qRT-PCR and western blotting.
Cai C; Zhou K; Jing J; Ren Y; Weng G; Cen D; Wang X; Huang S
Aging (Albany NY); 2023 Jul; 15(13):6117-6134. PubMed ID: 37432054
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
Front Med (Lausanne); 2022; 9():939776. PubMed ID: 36523779
[TBL] [Abstract][Full Text] [Related]
18. The potential of targeting cuproptosis in the treatment of kidney renal clear cell carcinoma.
Lei G; Tang L; Yu Y; Bian W; Yu L; Zhou J; Li Y; Wang Y; Du J
Biomed Pharmacother; 2023 Nov; 167():115522. PubMed ID: 37757497
[TBL] [Abstract][Full Text] [Related]
19. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
Wang L; Cao Y; Guo W; Xu J
J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis.
Li D; Wu X; Song W; Cheng C; Hao L; Zhang W
Ann Transl Med; 2022 Nov; 10(22):1235. PubMed ID: 36544675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
